Sep 19, 2025 7:40 am EDT OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT
Sep 12, 2025 7:40 am EDT OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit
Sep 03, 2025 7:40 am EDT OS Therapies to Participate in Upcoming Investor Conferences in September 2025
Sep 02, 2025 7:40 am EDT OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting
Sep 02, 2025 6:00 am EDT OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing
Aug 27, 2025 4:01 pm EDT OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025
Aug 19, 2025 6:00 am EDT OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug 14, 2025 5:44 pm EDT OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025
Aug 07, 2025 9:00 am EDT OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma